



Publications gateway number: GOV-17863

## **Pneumococcal polysaccharide conjugate vaccine (adsorbed) Risk Groups Patient Group Direction (PGD)**

This PGD is for the administration of pneumococcal polysaccharide conjugate vaccine (13-valent or 15-valent, adsorbed) (PCV) to individuals from 6 weeks of age with an underlying medical condition which puts them at increased risk from pneumococcal disease.

This PGD is for the administration of PCV13 or PCV15 vaccine by registered healthcare practitioners identified in [section 3](#), subject to any limitations to authorisation detailed in [section 2](#).

Reference no: PCV Risk Groups PGD  
Version no: v6.0  
Valid from: 28 February 2025  
Review date: 30 November 2026  
Expiry date: 31 May 2027

**The UK Health Security Agency (UKHSA) has developed this PGD to facilitate the delivery of the publicly funded immunisation in England in line with national recommendations.**

Those using this PGD must ensure that it is organisationally authorised and signed in Section 2 by an appropriate authorising person, relating to the class of person by whom the product is to be supplied, in accordance with Human Medicines Regulations 2012 (HMR2012)<sup>1</sup>. **The PGD is not legal or valid without signed authorisation in accordance with [HMR2012 Schedule 16 Part 2](#).**

Authorising organisations must not alter, amend or add to the clinical content of this document (sections 4, 5 and 6); such action will invalidate the clinical sign-off with which it is provided. In addition, authorising organisations must not alter section 3 (Characteristics of staff). Sections 2 and 7 can be edited within the designated editable fields provided, **but only for the purposes for which these sections are provided, namely the responsibilities and governance arrangements of the NHS organisation using the PGD. The fields in Section 2 and 7 cannot be used to alter, amend or add to the clinical content. Such action will invalidate the UKHSA clinical content authorisation which is provided in accordance with the regulations.**

Operation of this PGD is the responsibility of commissioners and service providers. The final authorised copy of this PGD should be kept by the authorising organisation completing Section 2 for 25 years after the PGD expires. Provider organisations adopting authorised versions of this PGD should also retain copies for the period specified above.

**Individual practitioners must be authorised by name, under the current version of this PGD before working according to it.**

Practitioners and organisations must check that they are using the current version of the PGD. Amendments may become necessary prior to the published expiry date. Current versions of UKHSA PGD templates for authorisation can be found from: [Immunisation patient group direction \(PGD\) templates](#)

---

<sup>1</sup> This includes any relevant amendments to legislation

Any concerns regarding the content of this PGD should be addressed to:  
[immunisation@ukhsa.gov.uk](mailto:immunisation@ukhsa.gov.uk)




Enquiries relating to the availability of organisationally authorised PGDs and subsequent versions of this PGD should be directed to: see contacts listed on page 5&6 of this PGD

## Change history

Version number	Change details	Date
v1.0 to v3.0	See earlier versions of this PGD for details	3 February 2017 to 14 February 2019
v4.0	PHE PCV13 Risk Groups PGD amended to: <ul style="list-style-type: none"> <li>• include primary immunisation schedule for those with asplenia, splenic dysfunction, complement disorder or severe immunocompromise under 1 year of age</li> <li>• include minor rewording, layout and formatting changes for clarity and consistency with other PHE PGD templates</li> </ul>	20 December 2019
v5.0	UKHSA PCV13 Risk Groups PGD amended to: <ul style="list-style-type: none"> <li>• include minor rewording of standard text, layout and formatting changes for clarity and consistency with organisation change and other UKHSA PGD and updated references</li> <li>• add a note in criteria for management of clusters and outbreaks of pneumococcal disease</li> <li>• add to cautions section information for premature infants and occurrence of apnoea following vaccination.</li> <li>• include the administration of an additional booster as per Green Book, Chapter 25</li> <li>• update the patient advice section in line with the Green Book Chapter 25</li> <li>• add to special considerations information for splenectomy immunisation post bone marrow transplant and timing of vaccination for leukaemia</li> </ul>	16 February 2022
v6.0	UKHSA PCV Risk Groups PGD amended to include: <ul style="list-style-type: none"> <li>• minor rewording, layout and formatting changes for clarity and consistency with other UKHSA PGD templates</li> <li>• details of a newly approved PCV15-valent vaccine (Vaxneuvance®)</li> <li>• recommendation for PCV15 in addition to PCV13, in line with Chapter 25 updates in the Green Book</li> <li>• updated considerations for individuals anticipated to receive a cochlear implant</li> <li>• clarification of exclusion criteria for at-risk individuals aged 2 years and above</li> <li>• clarification of the immunisation offer to at-risk individuals aged 10 years and over</li> <li>• interval between PPV23 and PCV doses for at-risk patients clarified as 8 weeks, not 2 months, in line with Table 25.3 of the Green Book</li> <li>• update of adverse reactions in common to both PCV vaccines</li> </ul>	23 January 2025

## 1. PGD development

This PGD has been developed by the following health professionals on behalf of the UKHSA:

Developed by:	Name	Signature	Date
<b>Pharmacist</b> (Lead Author)	Christina Wilson Lead Pharmacist- Immunisation Programmes, UKHSA		21 January 2025
<b>Doctor</b>	Professor Shamez Ladhani Paediatric Infectious Diseases Consultant, St George's Hospital London, Professor of Paediatric Infections and Vaccinology, St George's University London and Consultant Epidemiologist, Immunisation and Vaccine Preventable Diseases Division, UKHSA		21 January 2025
<b>Registered Nurse</b> (Chair of Expert Panel)	David Green Nurse Consultant for Immunisation Programmes, UKHSA		21 January 2025

This PGD has been peer reviewed by the UKHSA Immunisations PGD Expert Panel in accordance with the UKHSA PGD and Protocol Policy. It has been ratified by the UKHSA Medicines Governance Committee.

### Expert Panel

Name	Designation
Dr Nicholas Aigbogun	Consultant in Communicable Disease Control, Yorkshire and Humber Health Protection Team, UKHSA
Jess Baldasera	Health Protection Practitioner, North East Health Protection Team, Regions Directorate, UKHSA
Helen Beynon	Clinical Advisor, Immunisation Clinical Advice Response Service (CARS), NHSE London
Alison Campbell	Screening and Immunisation Coordinator, Clinical, NHSE Midlands
Jane Freeguard	Deputy Director of Vaccination – Medicines and Pharmacy, NHSE
Rosie Furner	Advanced Specialist Pharmacist, Medicines Governance (Patient Group Directions and Medicines Mechanisms) NHS Specialist Pharmacy Service
Ed Gardner	Advanced Paramedic Practitioner, Emergency Care Practitioner, Primary Care Based, Southbourne Surgery
Shilan Ghafoor	Medicines Governance Pharmacist, Medicines Governance, UKHSA
Greta Hayward	Consultant Midwife – Immunisation Programmes – UKHSA
Michelle Jones	Principal Medicines Optimisation Pharmacist, NHS Bristol North Somerset and South Gloucestershire Integrated Care Board
Elizabeth Lockett	Senior Screening and Immunisation Manager, NHSE South West
Dr Vanessa MacGregor	Consultant in Communicable Disease Control, East Midlands Health Protection Team, UKHSA
Lesley McFarlane	Lead Immunisation Nurse Specialist, Immunisation Programmes, UKHSA
Briony Mason	Screening and Immunisation Coordinator NHSE West Midlands
Tushar Shah	Lead Pharmacy Adviser, NHSE London


## 2. Organisational authorisations



The PGD is not legally valid until it has had the relevant organisational authorisation.

It is the responsibility of the organisation that has legal authority to authorise the PGD, to ensure that all legal and governance requirements are met. The authorising body accepts governance responsibility for the appropriate use of the PGD.

NHSE North East and Yorkshire authorises this PGD for use by the services or providers listed below:

Authorised for use by the following organisations or services
NHS England (NHSE) commissioned immunisation services or NHS Trust providing immunisation services.
Limitations to authorisation
Authorisation is limited to those registered practitioners listed in Section 3 who are employed by organisations/providers commissioned by NHSE North East and Yorkshire (NEY) to deliver immunisation programmes within the whole of the NHSE region of North East and Yorkshire

Organisational approval (legal requirement)			
Role	Name	Sign	Date
<b>Deputy Medical Director: System Improvement and Professional Standards</b> NHS England - North East and Yorkshire	<b>Dr James Gossow</b>		<b>7.2.2025</b>

Additional signatories according to locally agreed policy			
Role	Name	Sign	Date
<b>NHSE NEY PGD Governance assurance review</b> (Medicines Optimisation Pharmacist Lead, NHS NECS)	<b>Kurt Ramsden</b>		<b>7.2.2025</b>
<b>Screening and Immunisation Place Lead</b>  NHS England (NE and Yorkshire)	<b>Laura Brown</b>		<b>31.1.2025</b>

Local enquiries regarding the use of this PGD may be directed to your local screening and immunisation teams. See area-specific contacts below:

For North East and North Cumbria Area (i.e. Northumberland, Tyne & Wear, Durham Darlington and Tees and North Cumbria) use the following:

NHS England Screening and Immunisation Team:

email [england.cane.screeningimms@nhs.net](mailto:england.cane.screeningimms@nhs.net)

or NECS Medicine Optimisation Pharmacists: Kurt Ramsden: [kurtramsden@nhs.net](mailto:kurtramsden@nhs.net)

or Sue White: [sue.white14@nhs.net](mailto:sue.white14@nhs.net)

Please note - All North East and North Cumbria PGDs can be found at:

<https://medicines.necsu.nhs.uk/resources/patient-group-directions/>

For Yorkshire and Humber Area use the following:

West Yorkshire - [england.wysit@nhs.net](mailto:england.wysit@nhs.net)

South Yorkshire and Bassetlaw - [england.sybsit@nhs.net](mailto:england.sybsit@nhs.net)

North Yorkshire and Humber [ENGLAND.NYAHSIT@nhs.net](mailto:ENGLAND.NYAHSIT@nhs.net)

or the Health Protection Team Acute Response Centre (ARC): Contact Number: 0113 3860 300.

Please note - All Yorkshire and Humber PGDs can be found at: <https://www.england.nhs.uk/north-east-yorkshire/our-work/information-for-professionals/pgds/>

[Section 7](#) provides a practitioner authorisation sheet. Individual practitioners must be authorised by name to work to this PGD. Alternative practitioner authorisation sheets may be used where appropriate in accordance with local policy but this should be an individual agreement or a multiple practitioner authorisation sheet as included at the end of this PGD.

[Section 7](#) provides a practitioner authorisation sheet. Individual practitioners must be authorised by name to work to this PGD. Alternative practitioner authorisation sheets may be used where appropriate in accordance with local policy, but this should be an individual agreement or a multiple practitioner authorisation sheet as included at the end of this PGD.

### 3. Characteristics of staff

<p><b>Qualifications and professional registration</b></p>	<p>All practitioners should only administer vaccination where it is within their clinical scope of practice to do so. Practitioners must also fulfil the <a href="#">additional requirements</a> and <a href="#">continued training requirements</a> to ensure their competency is up to date, as outlined in the sections below.</p> <p>Practitioners working to this PGD must also be one of the following registered professionals who can legally supply and administer under a PGD:</p> <ul style="list-style-type: none"> <li>• nurses and midwives currently registered with the Nursing and Midwifery Council (NMC)</li> <li>• pharmacists and pharmacy technicians currently registered with the General Pharmaceutical Council (GPhC) (Note: This PGD is not relevant to privately provided community pharmacy services)</li> <li>• paramedics and physiotherapists currently registered with the Health and Care Professions Council (HCPC)</li> </ul> <p>Check <a href="#">Section 2</a> (Limitations to authorisation) to confirm whether all practitioners listed above have organisational authorisation to work under this PGD.</p>
<p><b>Additional requirements</b></p>	<p>Additionally, practitioners:</p> <ul style="list-style-type: none"> <li>• must be authorised by name as an approved practitioner under the current terms of this PGD before working to it</li> <li>• must have undertaken appropriate training for working under PGDs for supply and administration of medicines</li> <li>• must be competent in the use of PGDs (see <a href="#">NICE Competency framework for health professionals using PGDs</a>)</li> <li>• must be familiar with the vaccine product and alert to changes in the Summary of Product Characteristics (SPC), Immunisation Against Infectious Disease (the <a href="#">Green Book</a>) and national and local immunisation programmes</li> <li>• must have undertaken training appropriate to this PGD as required by local policy and in line with the <a href="#">National Minimum Standards and Core Curriculum for Immunisation Training</a></li> <li>• must be competent to undertake immunisation and to discuss issues related to immunisation</li> <li>• must be competent in the handling and storage of vaccines and management of the cold chain</li> <li>• must be competent in the recognition and management of anaphylaxis</li> <li>• must have access to the PGD and associated online resources</li> <li>• should fulfil any additional requirements defined by local policy</li> </ul> <p><b>The individual practitioner must be authorised by name, under the current version of this PGD before working according to it.</b></p>
<p><b>Continued training requirements</b></p>	<p>Practitioners must ensure they are up to date with relevant issues and clinical skills relating to immunisation and management of anaphylaxis, with evidence of appropriate Continued Professional Development (CPD).</p> <p>Practitioners should be constantly alert to any subsequent recommendations from the UKHSA, NHSE and other sources of medicines information.</p> <p>Note: the most current national recommendations should be followed but a Patient Specific Direction (PSD) may be required to administer the vaccine in line with updated recommendations outside of criteria specified in this PGD.</p>

#### 4. Clinical condition or situation to which this PGD applies

<p><b>Clinical condition or situation to which this PGD applies</b></p>	<p>Indicated for the active immunisation of individuals with an underlying medical condition which puts them at increased risk from pneumococcal disease in accordance with the national immunisation programme and recommendations given in <a href="#">Chapter 7</a> and <a href="#">Chapter 25</a> of Immunisation Against Infectious Disease: the Green Book.</p> <p>This PGD does not cover the routine childhood PCV immunisation programme which is covered by the UKHSA <a href="#">PCV PGD</a>.</p>
<p><b>Criteria for inclusion</b></p>	<p>Individuals who are:</p> <ul style="list-style-type: none"> <li>• under 2 years who have, or are anticipated to have asplenia, splenic dysfunction, complement disorder or severe immunocompromise<sup>2</sup> (see <a href="#">special considerations and additional information</a>)</li> <li>• from 2 years to under 10 years of age who are previously unvaccinated or partially vaccinated (such that they did not complete the routine PCV course as part of the national schedule) and who have a medical condition included in <a href="#">Appendix A</a></li> <li>• over 2 years of age and have, or are anticipated to have severe immunocompromise<sup>2</sup> (see <a href="#">special considerations and additional information</a>)</li> </ul> <p>Note: for the management of clusters and outbreaks of pneumococcal disease, see the <a href="#">PCV PGD</a>.</p>
<p><b>Criteria for exclusion<sup>3</sup></b></p>	<p>Individuals for whom valid consent or a best-interests decision in accordance with the <a href="#">Mental Capacity Act 2005</a>, has not been obtained (for further information on consent, see <a href="#">Chapter 2</a> of the Green Book). Several resources are available to inform consent (see <a href="#">written information to be given to individual or carer</a> section).</p> <p>Individuals who:</p> <ul style="list-style-type: none"> <li>• are less than 6 weeks of age</li> <li>• have received a dose of PCV (irrespective of valency) within the last 4 weeks (Note: national schedule recommends an 8 week interval, see <a href="#">dose and frequency of administration</a> section)</li> <li>• are aged 10 years or over and do not have (or are not anticipated to have) severe immunocompromise</li> <li>• are suffering from acute severe febrile illness (the presence of a minor infection is not a contraindication for immunisation)</li> <li>• have had a confirmed anaphylactic reaction to a previous dose of pneumococcal vaccine or to any component of the vaccine including diphtheria toxoid</li> </ul>

<sup>2</sup> Examples of severe immunocompromise include individuals with bone marrow transplant, acute and chronic leukaemia, multiple myeloma or genetic disorders affecting the immune system (such as IRAK-4, NEMO).

<sup>3</sup> Exclusion under this PGD does not necessarily mean the medication is contraindicated, but it would be outside its remit and another form of authorisation will be required.



<p><b>Cautions including any relevant action to be taken</b></p>	<p>Facilities for management of anaphylaxis should be available at all vaccination premises (see <a href="#">Chapter 8</a> of the Green Book and advice issued by the <a href="#">Resuscitation Council UK</a>).</p> <p>Whilst immunogenicity of the vaccine could be reduced in immunosuppressed individuals, vaccination is still recommended.</p> <p>Premature infants with asplenia, splenic dysfunction, complement disorder or severe immunocompromise<sup>2</sup> should be vaccinated in accordance with the Green Book <a href="#">Chapter 25</a> immunisation schedule and according to their chronological age.</p> <p>For premature infants without asplenia, splenic dysfunction, complement disorder or severe immunocompromise<sup>2</sup>, the <a href="#">PCV PGD</a> should be used.</p> <p>The occurrence of apnoea following vaccination is especially increased in infants who are born very prematurely. Very premature infants (born ≤28 weeks of gestation) who are in hospital should have respiratory monitoring for 48 to 72 hrs when given their first immunisation, particularly those with a previous history of respiratory immaturity. If the child has apnoea, bradycardia or desaturations after the first immunisation, the second immunisation should also be given in hospital, with respiratory monitoring for 48 to 72 hrs.</p> <p>Syncope (fainting) can occur following, or even before any vaccination especially in adolescents as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from faints.</p>
<p><b>Action to be taken if the individual is excluded</b></p>	<p>If aged less than 6 weeks, defer immunisation and provide an appointment as appropriate.</p> <p>If a dose of PCV (irrespective of valency) was received within the last 4 weeks, defer immunisation for an appropriate interval (see <a href="#">dose and frequency of administration</a>).</p> <p>Individuals aged 2 years and above with a clinical condition outlined in <a href="#">Appendix A</a>, should be prioritised for PPV vaccination over vaccination with PCV13 or PCV15. Refer to the <a href="#">PPV23 PGD</a> and ensure the individual's vaccination history is up to date in line with this PGD and recommendations as outlined in the Green Book, <a href="#">Chapter 25</a>.</p> <p>In case of postponement due to acute severe febrile illness, advise when the individual can be vaccinated and ensure another appointment is arranged.</p> <p>Seek appropriate advice from the local Screening and Immunisation Team, local Health Protection Team or the individual's clinician as required.</p> <p>The risk to the individual of not being immunised must be taken into account.</p> <p>Document the reason for exclusion and any action taken in the individual's clinical records.</p> <p>Inform or refer to the individual's GP or a prescriber as appropriate.</p>
<p><b>Action to be taken if the individual or carer declines treatment</b></p>	<p>Informed consent, from the individual or a person legally able to act on the person's behalf, must be obtained for each administration and recorded appropriately. Where a person lacks the capacity, in accordance with the <a href="#">Mental Capacity Act 2005</a>, a decision to vaccinate may be made in the individual's best interests. For further information on consent, see <a href="#">Chapter 2</a> of the Green Book.</p> <p>Advise the individual, parent or carer about the protective effects of the vaccine, the risks of infection and the potential complications.</p> <p>Document the advice given and the decision reached.</p> <p>Inform or refer to the individual's GP as appropriate.</p>

<b>Arrangements for referral for medical advice</b>	As per local policy
---	---------------------

## 5. Description of treatment

<b>Name, strength and formulation of drug</b>	Pneumococcal polysaccharide conjugate vaccine (adsorbed), either: <ul style="list-style-type: none"> <li>• <b>Prevenar<sup>®</sup> 13</b> (13-valent) suspension for injection in a pre-filled syringe</li> <li>• <b>Vaxneuvance<sup>®</sup></b> (15-valent) suspension for injection in a pre-filled syringe</li> </ul>
<b>Legal category</b>	Prescription only medicine (POM)
<b>Black triangle ▼</b>	Vaxneuvance <sup>®</sup> . As a new vaccine product, the Medicines and Healthcare products Regulatory Agency (MHRA) has a specific interest in the reporting of adverse drug reactions for this product. All suspected adverse drug reactions should be reported using the MHRA <a href="#">Yellow Card reporting scheme</a> .
<b>Off-label use</b>	<p><b>Infants &lt;37 weeks gestation</b></p> <p>Administration of a 2-dose primary series of Prevenar<sup>®</sup>13 or Vaxneuvance<sup>®</sup> to pre-term infants &lt;37 weeks gestation, with asplenia, splenic dysfunction, complement disorder or severe immunocompromise<sup>4</sup>, is contrary to the 3 dose primary schedule detailed in the SPCs but is in accordance with the recommendations for individuals with asplenia, splenic dysfunction, complement disorder or severe immunocompromise<sup>4</sup> in the Green Book, <a href="#">Chapter 7</a> and <a href="#">Chapter 25</a>.</p> <p><b>Individuals under 2 years</b></p> <p>Administration of an additional booster following a 2+1 schedule is off-label as the additional booster is not included in the SPC but is in accordance with the recommendations and <a href="#">Chapter 25</a> of the Green Book.</p> <p>Vaccines should be stored according to the conditions detailed in the <a href="#">Storage</a> section below. However, in the event of an inadvertent or unavoidable deviation of these conditions, refer to <a href="#">Vaccine Incident Guidance</a>. Where the vaccine is assessed in accordance with these guidelines as appropriate for continued use, this would constitute off-label administration under this PGD.</p> <p>Where a vaccine is recommended off-label consider, as part of the consent process, informing the individual, parent or carer that the vaccine is being offered outside of product licence but in accordance with national guidance.</p>
<b>Route and method of administration</b>  (continued over page)	<p>Administer by intramuscular injection, preferably into the anterolateral aspect of the thigh in infants under one year of age. The deltoid muscle of the upper arm may be used in individuals over one year of age.</p> <p>When administering at the same time as other vaccines, care should be taken to ensure that the appropriate route of injection is used for all vaccinations. The vaccines should be given at separate sites, preferably in different limbs. If given in the same limb, they should be given at least 2.5cm apart. The site at which each vaccine was given should be noted in the individual's records.</p> <p>Individuals with bleeding disorders may be vaccinated intramuscularly if, in the opinion of a doctor familiar with the individual's bleeding risk, vaccines or similar small volume intramuscular injections can be administered with reasonable safety by this route. If the individual receives medication or other treatment to reduce bleeding, for example treatment for haemophilia, intramuscular vaccination can be scheduled shortly after such medication or treatment is administered. Individuals on stable anticoagulation therapy, including individuals on warfarin who are up to date with their scheduled INR testing and whose latest INR was below the upper</p>

<sup>4</sup> Examples of severe immunocompromise include individuals with bone marrow transplant, acute and chronic leukaemia, multiple myeloma or genetic disorders affecting the immune system (such as IRAK-4, NEMO).

<p><b>Route and method of administration</b> (continued)</p>	<p>threshold of their therapeutic range, can receive intramuscular vaccination. A fine needle (equal to 23 gauge or finer calibre such as 25 gauge) should be used for the vaccination, followed by firm pressure applied to the site (without rubbing) for at least 2 minutes. The individual or carer should be informed about the risk of haematoma from the injection.</p> <p>Prevenar<sup>®</sup>13 is a uniform white suspension which may sediment during storage. The vaccine should be well shaken.</p> <p>Vaxneuvance<sup>®</sup> is an opalescent suspension. Holding the prefilled syringe horizontally, shake vigorously to uniformly distribute the suspension before administering the vaccine.</p> <p>The vaccine should be visually inspected for foreign particulate matter and other variation of expected appearance prior to preparation and administration. Should either occur, do not administer the vaccine and discard the syringe in accordance with local procedures.</p> <p>The vaccine <a href="#">SPC</a> provides further guidance on preparation and administration.</p>
<p><b>Dose and frequency of administration</b></p> <p>(continued over page)</p>	<p>Single 0.5ml dose per administration.</p> <p><b>Individuals aged under 1 year of age</b></p> <p>Individuals at increased risk of pneumococcal disease due to asplenia, splenic dysfunction, complement disorder or severe immunocompromise<sup>2</sup> should receive:</p> <ul style="list-style-type: none"> <li>• a 2-dose priming schedule of PCV13 or PCV15 vaccine with an 8 week interval<sup>5</sup> between priming doses administered in the first year of life (commencing no earlier than 6 weeks of age), then</li> <li>• a booster dose to be administered at one year of age (on or after the first birthday), then</li> <li>• a further booster dose, 8 weeks after the first booster</li> </ul> <p>All other individuals under 1 year of age should be fully vaccinated in accordance with the routine PCV immunisation programme (see the UKHSA <a href="#">PCV PGD</a> and the <a href="#">vaccination of individuals with uncertain or incomplete immunisation status</a> guidance).</p> <p><b>Individuals from 1 year to under 2 years of age</b></p> <p>Individuals with asplenia, splenic dysfunction (see <a href="#">Appendix A</a>), complement disorder or severe immunocompromise<sup>2</sup>, aged between their first and second birthday should receive:</p> <ul style="list-style-type: none"> <li>• their routine PCV13 or PCV15 booster scheduled on or shortly after their first birthday followed by</li> <li>• an additional booster dose of PCV13 or PCV15 with an interval of 8 weeks between the PCV13 or PCV15 booster doses.</li> </ul> <p>Note: This is the schedule to follow regardless of whether the child had none, one or 2 routine primary doses of PCV13 or PCV15 in infancy. The intervals may be reduced to 4 weeks if necessary, to ensure that the immunisation schedule is completed.</p> <p><b>Individuals from 2 years to under 10 years of age</b></p> <p>Excluding the severe immunocompromised<sup>6</sup>, no further doses are needed for individuals from 2 years to under 10 years of age with a medical condition</p>

<sup>5</sup> The immunisation interval may be reduced to 4 weeks if necessary, to ensure the immunisation schedule is completed.

<sup>6</sup> Examples of severe immunocompromise include individuals with bone marrow transplant, acute and chronic leukaemia, multiple myeloma or genetic disorders affecting the immune system (such as IRAK-4, NEMO).

<p><b>Dose and frequency of administration</b> (continued)</p>	<p>included in <a href="#">Appendix A</a>, who have completed the routine PCV immunisation schedule (with PCV13 or PCV15). Priority should be given to vaccinating such individuals with PPV23 from the age of 2 years (see the <a href="#">PPV23 PGD</a>). Individuals who are unvaccinated or partially unvaccinated should be offered a single dose of PCV13 or PCV15.</p> <p>Severely immunocompromised<sup>6</sup> individuals, who have not received an additional booster of PCV13 or PCV15 recommended between one and 2 years of age, should be offered a single dose of PCV13 or PCV15, <b>irrespective</b> of any routine childhood vaccinations they have already received.</p> <p><b>Individuals from 10 years of age</b></p> <p>Excluding the severely immunocompromised<sup>6</sup>, no further doses are needed for individuals from 10 years of age, with a medical condition included in <a href="#">Appendix A</a>. See <a href="#">special considerations and additional information</a> section (Individuals aged over 10 years of age)</p> <p>Severely immunocompromised<sup>6</sup> individuals who have not received an additional booster of PCV13 or PCV15, should be offered a single dose of PCV13 or PCV15, <b>irrespective</b> of any routine childhood vaccinations they have already received.</p> <p>PCV13, PCV15 or additional PPV23 doses are not needed if the individual received PPV23 in the previous 2 years.</p> <p><b>Pneumococcal polysaccharide vaccine (PPV23)</b></p> <p>Additionally, all individuals with a medical condition included in <a href="#">Appendix A</a> should receive a dose of PPV23 on or after their second birthday (see the <a href="#">PPV PGD</a>).</p> <p>Individuals eligible for both PCV13 (or PCV15) and PPV23 should have the PCV13 (or PCV15) dose first followed by PPV23 at least 8 weeks later.</p>
<p><b>Duration of treatment</b></p>	<p>Single 0.5ml dose, repeated at recommended intervals as outlined above in <a href="#">dose and frequency of administration</a>.</p>
<p><b>Quantity to be supplied and administered</b></p>	<p>Single 0.5ml dose per administration.</p>
<p><b>Supplies</b></p>	<p>PCV vaccine for additional doses from one year of age for at risk groups is not centrally procured and these should be ordered from the manufacturer or their wholesalers. Details are given in the Green Book <a href="#">Chapter 25</a>.</p> <p>Centrally purchased vaccines for the national routine childhood immunisation programme for the NHS can only be ordered via ImmForm, that is vaccines for use for primary immunisation and the booster at one year of age. Protocols for the ordering, storage and handling of vaccines should be followed to prevent vaccine wastage (see the Green Book <a href="#">Chapter 3</a>).</p>
<p><b>Storage</b>  (continued over page)</p>	<p>Store at +2°C to +8°C. Store in original packaging in order to protect from light. Do not freeze.</p> <p>Following a single temperature excursion, Prevenar<sup>®</sup>13 is stable at temperatures up to 25°C for a maximum of 4 days. At the end of this period, Prevenar<sup>®</sup>13 should be used within this timeframe or discarded in accordance with local procedures.</p> <p>Stability data indicates Vaxneuvance<sup>®</sup> is stable at temperatures up to 25°C for 48 hours.</p>

<b>Storage</b> (continued)	<p>This information is only intended to guide health care professionals in case of temporary temperature excursions.</p> <p>In the event of an inadvertent or unavoidable deviation of these conditions, vaccine that has been stored outside the conditions stated above should be quarantined and risk assessed on a case-by-case basis for suitability of continued off-label use or appropriate disposal. Refer to <a href="#">Vaccine Incident Guidance</a> and contact the manufacturer if specific advice on management of the temperature excursion is required.</p>
<b>Disposal</b>	<p>Equipment used for immunisation, including used vials, ampoules, or discharged vaccines in a syringe or applicator, should be disposed of safely in a UN-approved puncture-resistant sharps box, according to local waste disposal arrangements and NHSE guidance (<a href="#">HTM 07-01: safe and sustainable management of healthcare waste</a>).</p>
<b>Drug interactions</b>	<p>Immunological response may be diminished in those receiving immunosuppressive treatment. Vaccination is recommended even if the antibody response may be limited.</p> <p>PCV13 or PCV15 may be given at the same time as other vaccines, with the exception of PPV23,. Individuals eligible for both PCV13 (or PCV15) and PPV23 should have the PCV13 or PCV15 dose first, followed by PPV23 at least 8 weeks later.</p> <p>A detailed list of interactions is available from the product <a href="#">SPC</a>.</p>
<b>Identification and management of adverse reactions</b>	<p>Local reactions following vaccination are very common such as pain, swelling or redness at the injection site and decreased appetite.</p> <p>Other commonly reported adverse reactions include fever, irritability, fatigue, myalgia, rash and headache.</p> <p>Diarrhoea is a commonly reported reactions specific to Prevenar<sup>®</sup>13.</p> <p>Hypersensitivity reactions, such as bronchospasm, angioedema and anaphylaxis can occur but are rare.</p> <p>A detailed list of adverse reactions is available from the product <a href="#">SPC</a>.</p>
<b>Reporting procedure of adverse reactions</b>	<p>Healthcare professionals and individuals, parents and carers are encouraged to report suspected adverse reactions to the Medicines and Healthcare products Regulatory Agency (MHRA) using the <a href="#">Yellow Card reporting scheme</a> or by searching for MHRA Yellow Card in the Google Play or Apple App Store.</p> <p>Any adverse reaction to a vaccine should be documented in the individual's record and the individual's GP should be informed.</p>
<b>Written information to be given to the individual (or parent or carer)</b>	<p>Offer the marketing authorisation holder's patient information leaflet (PIL) provided with the vaccine.</p> <p>Immunisation promotional material may be provided as appropriate:</p> <ul style="list-style-type: none"> <li>• <a href="#">Splenoectomy leaflet</a></li> </ul> <p>For resources in accessible formats and alternative languages, please visit <a href="#">Home - Health Publications</a>. Where applicable, inform the individual or carer that large print, Braille or audio CD PILs may be available from emc accessibility (freephone 0800 198 5000) by providing the medicine name and product code number, as listed in the product's <a href="#">SPC</a>.</p>
<b>Advice and follow up treatment</b> (continued over page)	<p>Inform the individual, parent or carer of possible side effects and their management.</p> <p>Vaccination may not result in complete protection in all recipients.</p>





<p><b>Special considerations and additional information</b></p> <p>(continued over page)</p>	<p>Priority should be given to offering PPV23 to individuals listed in <a href="#">Appendix A</a> from the age of 2 years. As outlined in the <a href="#">dose and frequency of administration</a> section, further doses of PCV13 or PCV15 are not required if PPV23 has been given in the last 2 years.</p> <p><b>Pneumococcal polysaccharide vaccine (PPV23)</b></p> <p>Additionally, all individuals with a medical condition included in <a href="#">Appendix A</a> should receive a dose of PPV23 on or after their second birthday (see the <a href="#">PPV23 PGD</a>).</p>
<p><b>Records</b></p>	<p>The practitioner must ensure the following is recorded:</p> <ul style="list-style-type: none"> <li>• that valid informed consent was given or a decision to vaccinate was made in the individual's best interests in accordance with the <a href="#">Mental Capacity Act 2005</a></li> <li>• name of individual, address, date of birth and GP with whom the individual is registered</li> <li>• name of immuniser</li> <li>• name and brand of vaccine</li> <li>• date of administration</li> <li>• dose, form and route of administration of vaccine</li> <li>• quantity administered</li> <li>• batch number and expiry date</li> <li>• anatomical site of vaccination</li> <li>• advice given, including advice given if excluded or immunisation declined</li> <li>• details of any adverse drug reactions and actions taken</li> <li>• supplied via PGD</li> </ul> <p>Records should be signed and dated (or password-controlled on e-records).</p> <p>All records should be clear, legible and contemporaneous.</p> <p>This information should be recorded in the individual's GP record. Where vaccine is administered outside the GP setting, appropriate health records should be kept and the individual's GP informed.</p> <p>The local Child Health Information Services team (Child Health Records Department) must be notified using the appropriate documentation or pathway as required by any local or contractual arrangement.</p> <p>A record of all individuals receiving treatment under this PGD should also be kept for audit purposes in accordance with local policy.</p>



## 6. Key references

<b>Key references</b>	<p><b>Pneumococcal conjugate vaccine</b></p> <ul style="list-style-type: none"><li>• Immunisation Against Infectious Disease: The Green Book <a href="#">Chapter 7</a>, January 2020 and <a href="#">Chapter 25</a>, 27 July 2023</li><li>• Summary of Product Characteristics for Prevenar<sup>®</sup>13 suspension for injection, Pfizer Ltd. Last updated 12 October 2021 <a href="https://www.medicines.org.uk/emc/product/453">https://www.medicines.org.uk/emc/product/453</a></li><li>• Summary of Product Characteristics for Vaxneuvance<sup>®</sup> suspension for injection, Merck Sharpe and Dohme. Last updated 14 December 2023 <a href="https://www.medicines.org.uk/emc/product/13754">https://www.medicines.org.uk/emc/product/13754</a></li><li>• Vaccination of individuals with uncertain or incomplete immunisation status, last updated 30 August 2024 <a href="https://www.gov.uk/government/publications/vaccination-of-individuals-with-uncertain-or-incomplete-immunisation-status">https://www.gov.uk/government/publications/vaccination-of-individuals-with-uncertain-or-incomplete-immunisation-status</a></li></ul> <p><b>General</b></p> <ul style="list-style-type: none"><li>• NHSE Health Technical Memorandum 07-01: safe and sustainable management of healthcare waste. Updated 7 March 2023 <a href="https://www.england.nhs.uk/publication/management-and-disposal-of-healthcare-waste-htm-07-01/">https://www.england.nhs.uk/publication/management-and-disposal-of-healthcare-waste-htm-07-01/</a></li><li>• National Minimum Standards and Core Curriculum for Immunisation Training for registered healthcare practitioners. Published February 2018 <a href="https://www.gov.uk/government/publications/national-minimum-standards-and-core-curriculum-for-immunisation-training-for-registered-healthcare-practitioners">https://www.gov.uk/government/publications/national-minimum-standards-and-core-curriculum-for-immunisation-training-for-registered-healthcare-practitioners</a></li><li>• NICE Medicines Practice Guideline 2 (MPG2): Patient Group Directions. Published 27 March 2017 <a href="https://www.nice.org.uk/guidance/mpg2">https://www.nice.org.uk/guidance/mpg2</a></li><li>• NICE MPG2 Patient group directions: competency framework for health professionals using patient group directions. 4 January 2018 <a href="https://www.nice.org.uk/guidance/mpg2/resources">https://www.nice.org.uk/guidance/mpg2/resources</a></li><li>• UKHSA Immunisation Collection <a href="https://www.gov.uk/government/collections/immunisation">https://www.gov.uk/government/collections/immunisation</a></li><li>• Vaccine Incident Guidance <a href="https://www.gov.uk/government/publications/vaccine-incident-guidance-responding-to-vaccine-errors">https://www.gov.uk/government/publications/vaccine-incident-guidance-responding-to-vaccine-errors</a></li></ul>
-----------------------	---

## 7. Practitioner authorisation sheet

PCV Risk Groups PGD v6.0 Valid from: 28 February 2025 Expiry: 31 May 2027

Before signing this PGD, check that the document has had the necessary authorisations in [section 2](#). Without these, this PGD is not lawfully valid.

### Practitioner

By signing this PGD you are indicating that you agree to its contents and that you will work within it.

PGDs do not remove inherent professional obligations or accountability.

It is the responsibility of each professional to practise only within the bounds of their own competence and professional code of conduct.

I confirm that I have read and understood the content of this PGD and that I am willing and competent to work to it within my professional code of conduct.			
Name	Designation	Signature	Date

### Authorising manager

I confirm that the practitioners named above have declared themselves suitably trained and competent to work under this PGD. I give authorisation on behalf of <b>insert name of organisation</b> for the above named health care professionals who have signed the PGD to work under it.			
Name	Designation	Signature	Date

### Note to authorising manager

Score through unused rows in the list of practitioners to prevent practitioner additions post managerial authorisation.

This authorisation sheet should be retained to serve as a record of those practitioners authorised to work under this PGD.

## Appendix A: Clinical risk groups who should receive pneumococcal immunisation

(Green Book [Chapter 25](#), Table 25.2)

Clinical risk group	Examples (decision based on clinical judgement)
<b>Asplenia or dysfunction of the spleen</b>	This also includes conditions such as homozygous sickle cell disease and coeliac syndrome that may lead to splenic dysfunction.
<b>Chronic respiratory disease</b> (chronic respiratory disease refers to chronic lower respiratory tract disease)	This includes chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema; and such conditions as bronchiectasis, cystic fibrosis, interstitial lung fibrosis, pneumoconiosis and bronchopulmonary dysplasia (BPD). Children with respiratory conditions caused by aspiration, or a neurological disease (such as cerebral palsy) with a risk of aspiration. Asthma is not an indication, unless so severe as to require continuous or frequently repeated use of systemic steroids (as defined in Immunosuppression below).
<b>Chronic heart disease</b>	This includes those requiring regular medication and/or follow-up for ischaemic heart disease, congenital heart disease, hypertension with cardiac complications, and chronic heart failure.
<b>Chronic kidney disease</b>	Nephrotic syndrome, chronic kidney disease at stages 4 and 5 and those on kidney dialysis or with kidney transplantation. (Re-immunisation with PPV23 is recommended every 5 years)
<b>Chronic liver disease</b>	This includes cirrhosis, biliary atresia and chronic hepatitis.
<b>Diabetes</b>	Diabetes mellitus requiring insulin or oral hypoglycaemic drugs. This does not include diabetes that is diet controlled.
<b>Immunosuppression</b>	Due to disease or treatment, including individuals undergoing chemotherapy leading to immunosuppression, bone marrow transplant, asplenia or splenic dysfunction, complement disorder, HIV infection at all stages, multiple myeloma or genetic disorders affecting the immune system (such as IRAK-4, NEMO)  Individuals on or likely to be on systemic steroids for more than a month at a dose equivalent to prednisolone at 20mg or more per day (any age), or for children under 20kg, a dose of 1mg or more per kg per day.
<b>Individuals with cochlear implants</b>	It is important that immunisation does not delay the cochlear implantation. If not possible to schedule vaccination before the intervention, the vaccination should be given as soon as possible afterwards, as the risk of invasive pneumococcal disease is highest around the time of implant insertion.
<b>Individuals with cerebrospinal fluid leaks</b>	This includes leakage of cerebrospinal fluid such as following trauma or major skull surgery (does not include CSF shunts).